Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medtronic’s ICM Proves Cost-Effective In Preventing Recurrent Stroke

Executive Summary

A new study shows implantable cardiac monitors are a cost-effective tool for preventing recurrent strokes following a stroke suspected to be caused by atrial fibrillation.

You may also be interested in...



Cardiovascular Catch-Up: Cardiac Implants Puts Ring Around Tricuspid Annulus; Boston Scientific’s Acurate neo2 TAVR Progresses; Medtronic Promotes New Stroke Plan

This edition of Medtech Insight’s regular round-up of some recent cardiovascular technology news and conversations you may have missed, including updates from Cardiac Implants, Boston Scientific, HeartBeam and Medtronic.

Minute Insight: Trials Sponsored By Medtronic and Biosense Webster Show Benefits Of AFib Ablation

Results from two industry-supported clinical trials published in the last week offer more support for treating atrial fibrillation with catheter ablation rather than medication alone.

Cardio Catch-Up: More Conferences, More New Data From Abbott And Medtronic

Medtech Insight’s Cardiovascular Catch-Up highlights some of the recent news on cardiovascular tech innovations in the last two months. This edition focuses on news from conferences, held over the last two months, including the Heart Rhythm Society and the TVT Structural Heart Summit.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT143292

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel